JP2021503006A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503006A5
JP2021503006A5 JP2020544383A JP2020544383A JP2021503006A5 JP 2021503006 A5 JP2021503006 A5 JP 2021503006A5 JP 2020544383 A JP2020544383 A JP 2020544383A JP 2020544383 A JP2020544383 A JP 2020544383A JP 2021503006 A5 JP2021503006 A5 JP 2021503006A5
Authority
JP
Japan
Prior art keywords
binds
adbd
cancer
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503006A (ja
JP7356435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060902 external-priority patent/WO2019099440A1/en
Publication of JP2021503006A publication Critical patent/JP2021503006A/ja
Publication of JP2021503006A5 publication Critical patent/JP2021503006A5/ja
Priority to JP2023117930A priority Critical patent/JP7689161B2/ja
Application granted granted Critical
Publication of JP7356435B2 publication Critical patent/JP7356435B2/ja
Priority to JP2025087327A priority patent/JP2025122150A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544383A 2017-11-14 2018-11-14 多機能性免疫細胞療法 Active JP7356435B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023117930A JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762585770P 2017-11-14 2017-11-14
US62/585,770 2017-11-14
US201862717165P 2018-08-10 2018-08-10
US62/717,165 2018-08-10
PCT/US2018/060902 WO2019099440A1 (en) 2017-11-14 2018-11-14 Multifunctional immune cell therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117930A Division JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法

Publications (3)

Publication Number Publication Date
JP2021503006A JP2021503006A (ja) 2021-02-04
JP2021503006A5 true JP2021503006A5 (https=) 2021-12-23
JP7356435B2 JP7356435B2 (ja) 2023-10-04

Family

ID=66539901

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544383A Active JP7356435B2 (ja) 2017-11-14 2018-11-14 多機能性免疫細胞療法
JP2023117930A Active JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A Pending JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023117930A Active JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A Pending JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Country Status (13)

Country Link
US (3) US11730763B2 (https=)
EP (1) EP3710034A4 (https=)
JP (3) JP7356435B2 (https=)
KR (2) KR20250070609A (https=)
CN (1) CN111511383A (https=)
AU (2) AU2018368431B2 (https=)
BR (1) BR112020008939A2 (https=)
CA (1) CA3082410A1 (https=)
IL (2) IL274677B2 (https=)
MX (2) MX2020004935A (https=)
PH (1) PH12020550242A1 (https=)
SG (1) SG11202003168WA (https=)
WO (1) WO2019099440A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
RS67119B1 (sr) 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20250070609A (ko) 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
JP2023500799A (ja) * 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Cal-tコンストラクトおよびその使用
JP2023516089A (ja) * 2020-03-06 2023-04-17 アレタ・バイオセラピューティクス・インコーポレイテッド がんの治療のための組成物及び方法
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
EP4126243A4 (en) * 2020-03-27 2024-06-12 The Trustees of Indiana University Immunotherapeutic targets in multiple myeloma and methods for their identification
EP4210733B1 (en) * 2020-09-04 2024-11-06 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
MX2023011110A (es) * 2021-03-26 2023-11-23 Arcellx Inc Terapias de celulas inmunitarias multifuncionales.
CN117295820A (zh) * 2021-03-31 2023-12-26 盐野义制药株式会社 以ccr8作为抗原识别的嵌合抗原受体
CN118679180A (zh) * 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
CN116284438B (zh) * 2022-12-28 2026-02-03 杭州凯保罗生物科技有限公司 一种Claudin2-MAGEA3融合肿瘤抗原蛋白的制备方法及其应用
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
WO2025174812A1 (en) * 2024-02-12 2025-08-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
AU8822601A (en) 2000-07-31 2002-02-13 Biolex Inc Expression of biologically active polypeptides in duckweed
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
CN1665934B (zh) 2002-03-19 2010-05-26 国际植物研究所 GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
DK1587907T3 (da) 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CN101287503A (zh) 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
GB0907251D0 (en) 2009-04-28 2009-06-10 Univ Leiden Coplymers
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012167109A2 (en) 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
GB201306634D0 (en) 2013-04-11 2013-05-29 Univ Bristol Cage-like particles
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US10800828B2 (en) * 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
KR20160126340A (ko) 2015-04-23 2016-11-02 삼성전자주식회사 3중-나선 다발 단백질 및 이의 용도
JP6791951B2 (ja) * 2015-08-27 2020-11-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺ガンを患っている患者の生存時間を予測するための方法
CN108473575B (zh) 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
CN107254447B (zh) * 2017-06-01 2020-10-16 刘未斌 Anti AFP CAR-T细胞及其制备方法和应用
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20250070609A (ko) 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
RS67119B1 (sr) 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
MX2023011110A (es) 2021-03-26 2023-11-23 Arcellx Inc Terapias de celulas inmunitarias multifuncionales.

Similar Documents

Publication Publication Date Title
JP2021503006A5 (https=)
JP6867347B2 (ja) 免疫療法のためのエンゲージャー細胞
ES2951552T3 (es) Polipéptidos inmunomoduladores y composiciones y métodos relacionados
JP7082574B2 (ja) 免疫療法用改変細胞
KR102763121B1 (ko) 치료적 면역 세포의 효능의 향상 방법
CN108715859B (zh) 靶向cd22的嵌合抗原受体及其应用
CA3177829A1 (en) Chimeric antigen and t cell receptors and methods of use
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
AU2019243453A1 (en) Methods of making and using guidance and navigation control proteins
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
WO2019032916A1 (en) CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF
WO2019005641A1 (en) GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP2018504094A (ja) Fc受容体様5を標的とするキメラ抗原受容体およびその使用
JP2018529327A5 (https=)
AU2026201842A1 (en) Engineered cells, T cell immune modulating antibodies and methods for using the same
JP2015527070A5 (https=)
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
CN113195535A (zh) 用于连接表达car的免疫细胞与抗原呈递细胞的双特异性多肽及其用途
JP2023520410A (ja) Cd33を標的にするキメラ抗原受容体
JP2021514188A (ja) Foxp3標的因子組成物と養子細胞療法のための使用方法
JP2023535371A (ja) 免疫抑制シグナル伝達をリダイレクトするためのキメラMyD88受容体ならびに関連する組成物および方法
US20250222030A1 (en) NK cells for Cell Therapy
CN117999344A (zh) Nkg2d嵌合抗原受体和pd1抑制剂联合治疗癌症的方法和药物
NZ805406A (en) Multifunctional immune cell therapies